Pegylated interferon alpha-2b (Peg-IFN α-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN α-2b plus ribavirin.

MLA

Oze, T., et al. “Pegylated Interferon Alpha-2b (Peg-IFN α-2b) Affects Early Virologic Response Dose-Dependently in Patients with Chronic Hepatitis C Genotype 1 during Treatment with Peg-IFN α-2b plus Ribavirin.” Journal of Viral Hepatitis, vol. 16, no. 8, Aug. 2009, pp. 578–85. EBSCOhost, https://doi.org/10.1111/j.1365-2893.2009.01116.x.

APA

Oze, T., Hiramatsu, N., Yakushijin, T., Kurokawa, M., Igura, T., Mochizuki, K., Imanaka, K., Yamada, A., Oshita, M., Hagiwara, H., Mita, E., Ito, T., Inui, Y., Hijioka, T., Tamura, S., Yoshihara, H., Hayashi, E., Inoue, A., Imai, Y., & Kato, M. (2009). Pegylated interferon alpha-2b (Peg-IFN α-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN α-2b plus ribavirin. Journal of Viral Hepatitis, 16(8), 578–585. https://doi.org/10.1111/j.1365-2893.2009.01116.x

Chicago

Oze, T., N. Hiramatsu, T. Yakushijin, M. Kurokawa, T. Igura, K. Mochizuki, K. Imanaka, et al. 2009. “Pegylated Interferon Alpha-2b (Peg-IFN α-2b) Affects Early Virologic Response Dose-Dependently in Patients with Chronic Hepatitis C Genotype 1 during Treatment with Peg-IFN α-2b plus Ribavirin.” Journal of Viral Hepatitis 16 (8): 578–85. doi:10.1111/j.1365-2893.2009.01116.x.